Journal
ANNUAL REVIEW OF ANIMAL BIOSCIENCES, VOL 4
Volume 4, Issue -, Pages 199-222Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-animal-022114-110911
Keywords
cancer; comparative oncology; clinical trials; dog; preclinical model
Categories
Funding
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K01OD019923] Funding Source: NIH RePORTER
- NIH HHS [K01 OD019923] Funding Source: Medline
Ask authors/readers for more resources
Spontaneous cancers in client-owned dogs closely recapitulate their human counterparts with respect to clinical presentation, histological features, molecular profiles, and response and resistance to therapy, as well as the evolution of drug-resistant metastases. In several instances the incorporation of dogs with cancer into the preclinical development path of cancer therapeutics has influenced outcome by helping to establish pharmacokinetic/pharmacodynamics relationships, dose/regimen, expected clinical toxicities, and ultimately the potential for biologic activity. As our understanding regarding the molecular drivers of canine cancers has improved, unique opportunities have emerged to leverage this spontaneous model to better guide cancer drug development so that therapies likely to fail are eliminated earlier and therapies with true potential are optimized prior to human studies. Both pets and people benefit from this approach, as it provides dogs with access to cutting-edge cancer treatments and helps to insure that people are given treatments more likely to succeed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available